Sanofi Dupixent recommended for EU approval by CHMP for prurigo nodularis treatment Ruchika Sharma13 Nov 2022 11:00 AM GMTDupixent is a fully human monoclonal antibody that inhibits the signaling of the interleukin-4 (IL-4) and interleukin-13 (IL-13) pathways and is not...
Serum Dupilumab levels fail to reveal treatment response in Atopic Dermatitis at 16 weeks Dr.Niharika Harsha B3 Nov 2022 2:30 PM GMTA new clinical study found that serum dupilumab levels do not affect treatment response and adverse effects during the first year of treatment at 16...
Dupilumab reduces exacerbations and improves FEV1 in uncontrolled, moderate-to-severe asthma Dr.Niharika Harsha B24 Oct 2022 2:30 PM GMTA recent study found that in patients having uncontrolled, moderate-to-severe asthma Dupilumab showed sustained, long-term reduction in exacerbations...
Dupilumab associated with "highly favorable" outcomes in Type 2 Chronic Rhinosinusitis Dr Aditi Yadav6 Oct 2022 5:00 AM GMTSwitzerland: A recent study published in Allergy, European Journal of Allergy and Clinical Immunology, predicted treatment outcome as "highly...
FDA approves dupilumab as first and only treatment Indicated for Prurigo Nodularis Dr. Kamal Kant Kohli2 Oct 2022 2:00 PM GMTPrurigo nodularis is a chronic, debilitating skin disease with underlying type 2 inflammation and its impact on quality of life is one of the highest...
Sanofi Prurigo nodularis drug Dupixent gets USFDA okay Ruchika Sharma30 Sep 2022 11:00 AM GMTParis: Sanofi has announced that the U.S. Food and Drug Administration (USFDA) has approved Dupixent (dupilumab) for the treatment of adult patients...
Dupilumab significantly improves skin lesions and itching among treated patients with prurigo nodularis Dr. Kamal Kant Kohli21 Sep 2022 2:30 PM GMTDupilumab improves skin lesions and itching among treated patients with prurigo nodularis, reveals Initrial data presented at the European Academy of...
Sanofi, Regeneron Pharma announce positive Phase 3 data for Dupixent in adults with uncontrolled prurigo nodularis Ruchika Sharma10 Sep 2022 7:26 AM GMTPeople with prurigo nodularis experience intense, persistent itch, with thick skin lesions (called nodules) that can cover most of the body.
JAK inhibitors don't increase risk of VTE in Atopic Dermatitis patients: JAMA Dr.Niharika Harsha B30 Aug 2022 2:30 PM GMTThe use of JAK Inhibitors does not increase the risk of Venous thromboembolism in patients with Atopic Dermatitis as per a new study that was...
Abrocitinib bests dupilumab for treating moderate-to-severe atopic dermatitis: Lancet Dr. Shravani Dali18 Aug 2022 5:45 AM GMTAbrocitinib 200 mg per day is more efficacious than dupilumab in adults with moderate-to-severe atopic dermatitis according to a recent study...
Eczema drug dupilumab increases survival in COVID-19 patients Dr. Kamal Kant Kohli18 Aug 2022 5:30 AM GMTDupilumab a monoclonal antibody used to treat asthma and eczema can improve survival for patients with moderate to severe COVID-19, finds a clinical...
Sanofi gets CDSCO Panel okay to study Dupilumab Medical Dialogues Team19 July 2022 12:30 PM GMTNew Delhi: Directing to include all Serious Adverse Events (SAEs) and adverse events (AEs) of test drug in the informed consent document, the Subject...
